Description
Portrazza (necitumumab) is a monoclonal antibody medication that targets the epidermal growth factor receptor (EGFR) protein. It is used in combination with gemcitabine and cisplatin, to treat patients with metastatic squamous non-small cell lung cancer.
Uses:
Portrazza is used in combination with gemcitabine and cisplatin to treat patients with metastatic squamous non-small cell lung cancer. It is only indicated for use in patients with squamous non-small cell lung cancer and should not be used in patients with non-squamous non-small cell lung cancer.
Storage conditions:
Portrazza should be stored in a refrigerator between 2-8°C (36-46°F). The medication should not be frozen and should be protected from light.
Mechanism of action:
Portrazza targets the EGFR protein, which is overexpressed in certain types of cancer, including squamous non-small cell lung cancer. By binding to the EGFR protein, Portrazza prevents cancer cell growth and promotes cell death.
HOW TO USE:
Portrazza is administered intravenously in a medical setting by a healthcare professional. The first dose is given on the first day of each cycle, followed by weekly dosing in conjunction with gemcitabine and cisplatin.
Precautions:
Portrazza has been associated with severe side effects, including severe allergic reactions, skin reactions, and an increased risk of blood clots. Patients with pre-existing blood clotting disorders or allergy to Portrazza or any of its components should use Portrazza with caution.
Drug Interactions:
Portrazza may interact with other medications, particularly those that affect the liver or heart. Patients taking any medications that may affect liver or heart function should inform their healthcare provider before taking Portrazza.
Contraindications:
Portrazza is contraindicated in patients with a history of severe hypersensitivity to necitumumab or any component of the medication. It should not be used in patients with non-squamous non-small cell lung cancer.
Overdose:
There is currently no established protocol for Portrazza overdose. Medical attention should be sought immediately if an overdose is suspected.
Adverse reactions:
Common side effects of Portrazza include skin reactions, fatigue, nausea, diarrhea, rash, and decreased appetite. It may also cause severe allergic reactions, blood clots, and lung problems. Patients should inform their medical provider of any abnormal and persistent symptoms during treatment.
In conclusion, Portrazza is a monoclonal antibody medication that targets the EGFR protein, used in combination with gemcitabine and cisplatin, to treat patients with metastatic squamous non-small cell lung cancer. It is only indicated for use in patients with squamous non-small cell lung cancer and should not be used in patients with non-squamous non-small cell lung cancer. It is administered intravenously in a medical setting with weekly dosing. Patients with pre-existing blood clotting disorders or allergy to Portrazza or any of its components should use Portrazza with caution. Common side effects include skin reactions, fatigue, and nausea. Portrazza should be stored in a refrigerator between 2-8°C (36-46°F).
Reviews
There are no reviews yet.